Literature DB >> 26421934

Association of interleukin-10 levels with age of onset and duration of illness in patients with major depressive disorder.

Marta Gazal1, Karen Jansen2, Luciano D Souza2, Jean P Oses2, Pedro V Magalhães3, Ricardo Pinheiro2, Gabriele Ghisleni2, Luciana Quevedo2, Manuella P Kaster4, Flávio Kapczinski3, Ricardo A da Silva2.   

Abstract

OBJECTIVE: To investigate peripheral levels of interleukin-10 (IL-10) in patients with major depressive disorder (MDD) and bipolar disorder (BD) and evaluate the relationship between IL-10, age of disease onset, and duration of illness.
METHODS: Case-control study nested in a population-based cohort of 231 individuals (age 18-24 years) living in Pelotas, state of Rio Grande do Sul, Brazil. Participants were screened for psychopathology using the Mini-International Neuropsychiatric Interview (MINI) and the Structured Clinical Interview for DSM-IV (SCID-I). Serum IL-10 was measured using commercially available immunoassay kits.
RESULTS: Peripheral levels of IL-10 were not significantly different in individuals with MDD or BD as compared to controls. However, higher IL-10 levels were found in MDD patients with a later disease onset as compared with controls or early-onset patients. In addition, IL-10 levels correlated negatively with illness duration in the MDD group. In the BD group, age of onset and duration of illness did not correlate with IL-10 levels.
CONCLUSION: Higher levels of IL-10 are correlated with late onset of MDD symptoms. Moreover, levels of this cytokine might decrease with disease progression, suggesting that an anti-inflammatory balance may be involved in the onset of depressive symptoms and disease progression in susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26421934     DOI: 10.1590/1516-4446-2014-1452

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


  7 in total

1.  Are Cardiovascular Risk Factors Stronger Predictors of Incident Cardiovascular Disease in U.S. Adults With Versus Without a History of Clinical Depression?

Authors:  Brittanny M Polanka; Jessica Berntson; Elizabeth A Vrany; Jesse C Stewart
Journal:  Ann Behav Med       Date:  2018-11-12

2.  Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression.

Authors:  Wei Zou; Renjie Feng; Yuan Yang
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

3.  Expression of Bcl-2 and Bax genes in peripheral blood lymphocytes of depressed and nondepressed individuals.

Authors:  Meisam Amidfar; Zahra Karami; Gholam Reza Kheirabadi; Hamid Afshar; Abolghasem Esmaeili
Journal:  J Res Med Sci       Date:  2019-05-22       Impact factor: 1.852

4.  Altered serum interleukin-7 and interleukin-10 are associated with drug-free major depressive disorder.

Authors:  Sadia Anjum; M M A Shalahuddin Qusar; Mohammad Shahriar; Sardar Mohammad Ashraful Islam; Mohiuddin Ahmed Bhuiyan; Md Rabiul Islam
Journal:  Ther Adv Psychopharmacol       Date:  2020-04-28

5.  Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies.

Authors:  Lucia Carboni; Dennis J McCarthy; Bruno Delafont; Michele Filosi; Elena Ivanchenko; Emiliangelo Ratti; Susan M Learned; Robert Alexander; Enrico Domenici
Journal:  Transl Psychiatry       Date:  2019-08-02       Impact factor: 6.222

6.  Chronically reduced IL-10 plasma levels are associated with hippocampal sclerosis in temporal lobe epilepsy patients.

Authors:  Pabitra Basnyat; Marko Pesu; Mikael Söderqvist; Anna Grönholm; Suvi Liimatainen; Maria Peltola; Jani Raitanen; Jukka Peltola
Journal:  BMC Neurol       Date:  2020-06-12       Impact factor: 2.474

Review 7.  Correlation between Mild Traumatic Brain Injury-Induced Inflammatory Cytokines and Emotional Symptom Traits: A Systematic Review.

Authors:  Shazia Malik; Omar Alnaji; Mahnoor Malik; Teresa Gambale; Michel Piers Rathbone
Journal:  Brain Sci       Date:  2022-01-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.